Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

Autor: Eliot A. Brinton, Uma Kher, Sukrut Shah, Christopher P. Cannon, Michael Davidson, Antonio M. Gotto, Tanya B. Ashraf, Christine McCrary Sisk, Hayes Dansky, Yale Mitchel, Philip Barter, M. Gerstman, L. Howes, K. Kostner, P. Nestel, D. Sullivan, H. Brath, J. Patsch, B. Paulweber, H. Toplak, C.M. Constance, E. Howlett, D. Mymin, L. Pliamm, K.K. Saunders, J.-C. Tardif, R. Tytus, P. Aschner, S. Keinänen-Klukaanniemi, T. Strandberg, M.-R. Taskinen, G. Luc, D. Richter, J.L. Schlienger, Y. Zaïr, K.-F. Appel, M. Baar, C. Luley, U. Overhoff, T. Pomykaj, T. Schaefer, S.T. Lau, K.L.F. Lee, K. Tan, B. Tomlinson, M.W. Tsang, K. Badacsonyi, Á. Kalina, N. Kanakaridisz, L. Márk, É. Péterfai, L. Regos, I. Reiber, J. Takács, A. Vértes, A. Elis, D. Gavish, D. Harats, O. Hussein, T. Hayek, E. Leitersdorf, A.K. Bin Abdul Ghapar, K.H. Chee, S.B. Ismail, K.H. Ling, G.R.L. Ramanathan, K.H. Sim, R. Alvarado, M. Benavides, G.E. Cardona, G. Gonzalez, J. Verdejo, D.C.G. Basart, B.P.M. Imholz, J.J.C. Jonker, P.R. Nierop, J.L. Posma, Th.B. Twickler, E. Barrington-Ward, R. Cutfield, D.H. Friedlander, R.S. Scott, H. Istad, G. Langslet, G.K. Skjelvan, S.J. Campodónico Hoyos, R. Coloma Araniya, A. Gallegos C., C.A. Pino Morales, L. Watanabe, G.P. Arutyunov, A.B. Blokhin, M.G. Bubnova, S.Y. Marcevich, C. Álvarez Sánchez, L.A. Álvarez-Sala Walther, B. Gil Extremera, F. Perez Jimenez, L. de Teresa Parreño, C.-P. Anderberg, U. Hedin, A. Hellberg, P. Höök, T. Kjellström, P. Nilsson, A.G. Olsson, U. Rosenqvist, K. Tolagen, T. Wolff, A. Baskin, H.E. Bays, R.I. Bernstein, N. Bittar, E.A. Brinton, L.H.K. Chee, R.A. Cottiero, R.D. D'Agostino, M.H. Davidson, P.S. Denker, R.K. Garcia, R.K. Hippert, T. Isakov, S.R. Kaster, B. Kerzner, E.J. Klein, M.J. Koren, M.E. Kutner, D. Liljenquist, D.G. Lorch, R. Lorraine, B.C. Lubin, N.M. Lunde, T.J. Majchrzak, J.M. McKenney, S. Mukherjee, D.D. Muse, M.S. Otruba, J.E. Pappas, K. Patrick, S.J. Powell, E. Riffer, L.D. Rink, J.L. Rohlf, J.B. Rosen, P.D. Rosenbilt, E.M. Roth, C.J. Rubenstein, J. Rubino, L.A. Rudolph, A. Schneider, W.G. Short, J.C. Silverfield, D.P. Suresh, G.A. Tarshis, P.D. Toth, R.W. Townsend, T.O. Wahl

Publikováno v: Journal of clinical lipidology

Background In the Determining the Efficacy and Tolerability of cholesteryl ester transfer protein (CETP) INhibition with AnacEtrapib (DEFINE) trial, anacetrapib added to statin produced robust low-density lipoprotein cholesterol (LDL-C)-lowering and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed0c778769d9b9d7a78e7c69d7f43bd3
https://pubmed.ncbi.nlm.nih.gov/25670362

Acute alcohol intoxication and brain function monitoring

Autor: J. Hannam, Paul S. Myles, D. Mcilroy, Alan Merry, M. Gerstman, S. Mitchell

Publikováno v: European Journal of Anaesthesiology. 31:47

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27af1d23b0413fd424adccfea921c888
https://doi.org/10.1097/00003643-201406001-00131

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Fever as an adverse reaction to carbamazepine

Autor: R. W. King, M. Gerstman, William P. Sheridan

Publikováno v: Australian and New Zealand journal of medicine. 12(5)

Fever as an adverse reaction to carbamazepine. W. P. Sheridan, R. W, King and M. Gerstman. Aust. N.Z. J. Med., 1982,12, pp. 520–522. Two middle-aged women developed fever and abnormal liver function tests while taking carbamazepine. In one case the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::588ae6e75d35e77cc16240c4254b476b
https://pubmed.ncbi.nlm.nih.gov/6960873

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.